PPBT Purple Biotech Ltd. Stock Quote

PPBT [NASD]

Index	-	P/E	-	EPS (ttm)	-	Insider Own	1.88%	Shs Outstand	17.51M	Perf Week	-4.67%
Market Cap	67.94M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	16.24M	Perf Month	-4.43%
Income	-	PEG	-	EPS next Q	-	Inst Own	24.90%	Short Float	1.88%	Perf Quarter	-37.12%
Sales	1.00M	P/S	67.94	EPS this Y	-	Inst Trans	-	Short Ratio	0.70	Perf Half Y	-5.13%
Book/sh	-	P/B	-	EPS next Y	-	ROA	-	Target Price	-	Perf Year	-20.59%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	3.60 - 14.40	Perf YTD	1.84%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-73.68%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	5.28%	ATR	0.22
Employees	13	Current Ratio	-	Sales Q/Q	-	Oper. Margin	-	RSI (14)	37.16	Volatility	4.07% 5.66%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.47	Prev Close	3.88
Shortable	Yes	LT Debt/Eq	-	Earnings	Mar 02 BMO	Payout	-	Avg Volume	434.01K	Price	3.79
Recom	-	SMA20	-9.33%	SMA50	-11.64%	SMA200	-18.44%	Volume	140,000	Change	-2.32%

Apr-23-21 08:00AM	Purple Biotech Announces Dosing of First Patient in Phase 1b/2 Clinical Trial of CM24 in Advanced Cancer Patients GlobeNewswire
Apr-13-21 08:17AM	Purple Biotech Presents Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting GlobeNewswire
Mar-19-21 08:00AM	Purple Biotech Announces Initiation of Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers GlobeNewswire
Mar-11-21 08:02AM	Purple Biotech to Present Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting GlobeNewswire
Mar-03-21 07:00AM	Purple Biotech Appoints Biopharmaceutical Industry Veteran Robert Gagnon to Board of Directors GlobeNewswire
Mar-02-21 07:00AM	Purple Biotech Provides Corporate Update and Reports Second Half and Full Year 2020 Financial Results GlobeNewswire -6.32%
Jan-18-21 07:41AM	Purple Biotech to Present at the B. Riley Oncology Investor Conference GlobeNewswire
Jan-04-21 09:40AM	Purple Biotech to Ring the Nasdaq Stock Market Opening Bell GlobeNewswire +6.56%

Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs in the United States. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension. Its oncology pipeline includes NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. was founded in 2010 and is headquartered in Rehovot, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience